Drug price regulator NPPA today said it has decided not to stop any coronary stent manufacturer from withdrawing products from the Indian market.
The National Pharmaceutical Pricing Authority (NPPA) said however that the companies will have to follow mandatory requirement of informing it six months in advance as prescribed under Drugs Prices Control Order (DPCO), 2013, while also following the ceiling price.
"In this connection, it is informed that NPPA has in-principle decided not to disallow any application submitted for withdrawal of stents from the market by stent manufacturer/importers," NPPA said in an office memorandum.
Under DPCO 2013, a manufacturer is required to inform NPPA at least six months prior to the intended date of discontinuation and also "follow ceiling price in such a manner and till such a time prescribed the government".
Last week, the government had revised ceiling prices of bare metal stents and drug eluting ones, almost a year after it slashed rates of coronary stents by up to 85 per cent. In case of bare metal stents (BMS), the government has increased the prices from current Rs 7,400 to Rs 7,660. On the other hand price of drug eluting stents (DES) has come down to Rs 27,890 from Rs 30,180.
In April last year, the NPPA had rejected applications by multinational firms Abbott and Medtronic to withdraw their advanced coronary stents from India while asking them to maintain supplies of the products.
The authority had asked the companies to consider options for price revision before deciding to withdraw their products from the market.
Prior to that, the NPPA had brought stents under price control and capped ceiling price of coronary stents at Rs 7,260 for bare metal variety and Rs 29,600 for drug-eluting ones.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)